KRRO
Korro Bio, Inc. · Healthcare
Insiders bought $20.8M of Korro Bio, Inc. in the last 12 months
10 insiders bought on 2 days.
KRRO over the last year
Largest buyers, last 12 months
KRRO after insider buys
3 months after each buy, from the first price a copier could get.
3 buys since 2024 with 3 months of prices.
Every filing
37 insider filings since 2023, newest first
Jean Francois Formela · Director
Oliver Dolan · Senior Vice President, Finance
Jean Francois Formela · Director
Jean Francois Formela · Director
Lynx1 Capital Management LP · 10% owner
Ram Aiyar · President and CEO
Jean Francois Formela · Director
Jean Francois Formela · Director
Todd Chappell · Chief Operating Officer
Loic A Vincent · Chief Scientific Officer
Jeffrey Cerio · General Counsel
Oliver Dolan · Senior Vice President, Finance
Ram Aiyar · President and CEO
Jean Francois Formela · Director
Rick Yang · 10% owner
Scott D Sandell · 10% owner
New Enterprise Associates 17, L.P. · 10% owner
Carmen Chang · 10% owner
Forest Baskett · 10% owner
Edward T Mathers · 10% owner
Mohamad Makhzoumi · 10% owner
Paul Edward Walker · 10% owner
Anthony A. Florence Jr. · 10% owner
Vineet Agarwal · CFO
Vineet Agarwal · CFO
New Enterprise Associates 17, L.P. · 10% owner
Forest Baskett · 10% owner
Anthony A. Florence Jr. · 10% owner
Paul Edward Walker · 10% owner
Carmen Chang · 10% owner
Edward T Mathers · 10% owner
Rick Yang · 10% owner
Mohamad Makhzoumi · 10% owner
Scott D Sandell · 10% owner
Atlas Venture Opportunity Fund Ii, L.P. · 10% owner
David L. Lucchino · Director
David L. Lucchino · Director
About Korro Bio, Inc.
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.